New Lung Cancer Drug Demonstrates Survival Benefit in Chinese Study

Data from the HARMONi-6 study, presented at ASCO 2026, indicates that ivonescimab, combined with chemotherapy, improved overall survival for patients with advanced squamous non-small cell lung cancer. This pivotal Chinese trial addresses a significant unmet medical need for this type of cancer, which typically has a poor prognosis. The findings suggest a potential new treatment option.